Frontiers in Pharmacology · 2018 · 178 citations · 43 references
Life SciencesImmunologyPharmacologyBiochemical PharmacologyInflammationInnate ImmunityAnti-inflammatory PharmacologyAntioxidant DefenseInflammatory SignalingNeuroprotectionOxidative Stress In InflammationReactive Oxygen SpeciesAntioxidant Defense MechanismsAntioxidant PharmacologyM1 Macrophage PhenotypesMacrophage Oxidative StressNitric OxideNrf2 Pathway ActivationNrf2 Signaling PathwayReactive Oxygen Species Generation
, TNF-α, and IL-6 in LPS-stimulated THP-1 macrophages. Furthermore, DC inhibited the macrophage M1 phenotype and the production of reactive oxygen species (ROS) in LPS-activated RAW264.7 cells. Mechanism studies showed that DC mainly activated nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway, increased the level of anti-oxidant protein heme oxygenase-1 (HO-1) and thus produced the anti-inflammatory and anti-oxidant effects, which were abolished by Nrf2 siRNA and HO-1 inhibitor. These findings suggested that DC could be a new Nrf2 activator for the treatment and prevention of diseases related to inflammation and oxidative stress.
43
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text
Medicine, Neurology, Pharmacotherapy +17